<SEC-DOCUMENT>0001213900-25-075656.txt : 20250813
<SEC-HEADER>0001213900-25-075656.hdr.sgml : 20250813
<ACCEPTANCE-DATETIME>20250813160520
ACCESSION NUMBER:		0001213900-25-075656
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250813
DATE AS OF CHANGE:		20250813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BiomX Inc.
		CENTRAL INDEX KEY:			0001739174
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				823364020
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275935
		FILM NUMBER:		251211474

	BUSINESS ADDRESS:	
		STREET 1:		22 EINSTEIN ST.
		STREET 2:		FLOOR 4
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7414003
		BUSINESS PHONE:		972 723942377

	MAIL ADDRESS:	
		STREET 1:		22 EINSTEIN ST.
		STREET 2:		FLOOR 4
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7414003

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chardan Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20180430
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0252937-424b5_biomx.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: right; text-indent: -45pt"><B>Filed pursuant to
Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: right; text-indent: -45pt"><B>Registration No.
333-275935</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<B>to Prospectus dated January 2, 2024</B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 135px; width: 244px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: center; text-indent: 0.4in"><B>Up to
$1,765,939</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: center; text-indent: 0.4in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: center; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: center; text-indent: 0.4in"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in"><FONT STYLE="background-color: white">This
prospectus supplement amends and supplements the information in the prospectus, dated January 2, 2024, filed as a part of our registration
statement on Form S-3 (File No. 333-275935), or the Registration Statement, as supplemented by our prospectus supplement, dated February
24, 2025, or collectively, the Prior Prospectus, relating to the offering, issuance and sale by us of our shares of common stock, par
value $0.0001 per share, or the Common Stock from time to time that may be issued and sold under the At-the-Market Offering Agreement,
dated December 7, 2023, or the offering agreement, by and between us and H.C. Wainwright &amp; Co., LLC, or Wainwright, as sales agent.
This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the
extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement
is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or
supplements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.15in 0 0; text-align: justify; text-indent: 0.4in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.15in 0 0; text-align: justify; text-indent: 0.4in">We are filing this prospectus supplement to amend the Prior Prospectus, to update the maximum amount of securities
we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations
and the current public float of our shares of Common Stock and in accordance with the terms of the offering agreement, we may offer and
sell ADSs having an aggregate offering price of up to $1,765,939 from time to time through Wainwright, which does not include the shares
of Common Stock having an aggregate sales price of approximately $20,734 that were sold pursuant to the Prior Prospectus to date. In
the event that we may sell additional amounts under the offering agreement and in accordance with General Instruction I.B.6, we will
file another prospectus supplement prior to making such additional sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">The aggregate market value of our shares
of Common Stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $15,441,621, which was calculated based on
23,756,340 shares of Common Stock outstanding held by non-affiliates and at a price of $0.65 per share of Common Stock, the closing price
of our shares of Common Stock on August 6, 2025, a date that is within 60 days of filing this prospectus supplement. <FONT STYLE="background-color: white">We
have sold an aggregate of approximately $</FONT>3,381,268 <FONT STYLE="background-color: white">of securities pursuant to General Instruction
I.B.6. of Form S-3 during the 12-calendar month calendar period that ends on, and includes, the date of this </FONT>prospectus supplement.
As a result of the limitations of General Instruction I.B.6 of Form S-3, and in accordance with the terms of the offering agreement,
we currently have the capacity to sell shares of our Common Stock under the offering agreement having an aggregate offering price of
up to $1,765,939 from time to time through Wainwright.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">Our common stock
is listed on the NYSE American under the symbol &ldquo;PHGE.&rdquo; On August 12, 2025, the last reported sale price of our Common Stock
on the NYSE American was $0.56 per share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.4in"><B>Investing in
our securities involves significant risks. See &ldquo;Risk Factors&rdquo; beginning page 7 of the Prospectus and under the heading &ldquo;Risk
Factors&rdquo; included in our most recent annual report on Form 10-K, which is incorporated by reference into the Prospectus, and under
similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement
and the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: justify; text-indent: 0.4in"><B>Neither the Securities
and Exchange Commission nor any state or other securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
H.C. Wainwright &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is August
13, 2025</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "' /0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 445B2>+='BE>*2X=71BK*8FR"/PII-[$3J0A\;L;=%8/\
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M:UC5G=V1ZF6X7DC[66[V] HHHK$]4\Q^._\ R3Z+_K_B_P#07KYOKZ0^._\
MR3Z+_K_B_P#07KYOKNP_P&4]RYI>K7^B7ZWVF73VMTJE5E3&0#U'(K=D^)'C
M26-D;Q)>[6&#MVJ?S R*H>%/#5SXM\01:/:3Q032([AY02H"C)Z5W[? #Q %
M)76-,)[ K(,_I5RE33]X23Z'DY)9BS$EB<DDY)-=Q\-O!VC>*M8C35M9MX55
MLC3P2LUQCMDX&/H2?IUKE]=T._\ #FL3Z5J<0CNH<9"ME6!Y# ]P:SU9D=71
MF5U(964X*D="#V-4_>6C%L?2WQHBC@^%\T42*D<<\"HBC 4!@ !7S17L.L>+
M)O%?P%FDO7WW]G>0V]P_=\,"KGW((S[@UX]6=!.,6GW*D[L[WX-$+\3K DX
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
